Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc. (NBIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Neurocrine is a neuroscience-focused biopharmaceutical company. Its commercial portfolio includes INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and CRENESSITY (crinecerfont), launched in December 2024 for classic congenital adrenal hyperplasia (CAH). The company also holds royalty rights to AbbVie's elagolix products and MTPC's valbenazine products in select Asian markets.
Key Financial Metrics
| Financial Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $794.9 | $622.1 | $2,055.0 | $1,727.6 |
| Net Product Sales | $789.9 | $616.6 | $2,035.6 | $1,709.4 |
| Operating Income | $239.0 | $183.8 | $408.2 | $428.5 |
| Net Income | $209.5 | $129.8 | $324.9 | $238.2 |
| Diluted EPS | $2.04 | $1.24 | $3.19 | $2.29 |
| Operating Cash Flow (9M) | $394.3 (2025) vs $352.9 (2024) | |||
| Cash & Equivalents (Sep 30, 2025) | $340.2 | |||
| Total Assets (Sep 30, 2025) | $4,265.7 | |||
| Working Capital (Sep 30, 2025) | $1,520.4 |
Debt & Liquidity: The company settled its convertible senior notes in May 2024. As of September 30, 2025, there is no long-term debt reported on the balance sheet. Total cash, cash equivalents, and marketable securities stood at $2,113.3 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 27.8% year-over-year in Q3 2025 and 19.0% for the nine-month period. This was driven by a 12.0% increase in INGREZZA sales and the contribution of $98.1 million in CRENESSITY sales in Q3 (launched Dec 2024).
- Profitability: Net income increased 61.4% in Q3 2025 compared to Q3 2024. The nine-month net income increased 36.4%.
- Expense Increases:
- R&D: Increased to $250.0 million in Q3 2025 (vs. $195.0 million in Q3 2024) due to investments in Phase 3 programs for osavampator (MDD) and direclidine (schizophrenia).
- SG&A: Increased to $291.6 million in Q3 2025 (vs. $234.3 million in Q3 2024) reflecting commercial expansion for INGREZZA and CRENESSITY.
- Other Income: Significant improvement in "Other income (expense)" due to a $30.6 million unrealized gain on equity investments in Q3 2025, compared to a $16.9 million loss in Q3 2024. Additionally, Q3 2024 included $138.4 million in charges related to convertible senior notes which were absent in 2025.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Commercial Strategy: Focus on maximizing INGREZZA and CRENESSITY through sales team expansion (targeting completion by Q1 2026) and improved formulary access (approx. 70% of TD/Huntington's Medicare beneficiaries).
- Pipeline Progress: Initiated Phase 3 studies for direclidine (schizophrenia) and osavampator (MDD). Initiated Phase 1 studies for NBIP-1435 (CAH), NBI-921355 (epilepsy), and NBI-1140675 (VMAT2 inhibitor).
- Capital Allocation: Authorized a $500 million share repurchase program in Feb 2025; $167.7 million utilized in the first nine months of 2025, with $332.3 million remaining.
Risks and Contingencies:
- Legal Proceedings: Filed suit against Zydus Lifesciences regarding a generic ANDA for INGREZZA SPRINKLE. Also engaged in patent disputes with Spruce Biosciences.
- Regulatory: Received an FDA untitled letter in September 2025 regarding promotional claims for INGREZZA. The company believes its ads comply with laws but is addressing the concerns.
- Legislative: Potential impact of the "One Big Beautiful Bill Act" (OBBBA) on tax provisions and Medicaid spending. INGREZZA currently qualifies for the small biotech exception to Medicare price negotiation until 2027.
- Supply Chain: Reliance on third-party manufacturers in Europe exposes the company to potential tariff risks and geopolitical disruptions.
Investor Verification Checklist
- CRENESSITY Adoption: Verify the trajectory of CRENESSITY sales post-launch to ensure it meets commercial expectations given the small patient population for CAH.
- INGREZZA Patent Litigation: Monitor the outcome of the lawsuit against Zydus Lifesciences regarding the generic INGREZZA SPRINKLE ANDA.
- Phase 3 Data Readouts: Track upcoming data releases for direclidine (schizophrenia) and osavampator (MDD), which are critical for future revenue diversification.
- Regulatory Compliance: Review the resolution of the FDA untitled letter regarding INGREZZA promotional materials to assess potential impact on marketing spend or sales.
- Share Repurchase Execution: Monitor the pace of the remaining $332.3 million share repurchase authorization and its impact on diluted share count.